Germline genetic testing to predict drug response and toxicity in oncology--reality or fiction?
Annals of the Academy of Medicine, Singapore
;
: 350-355, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-229654
ABSTRACT
In addition to 6-mercaptopurine, 5-fluorouracil and irinotecan, the United States Food and Drug Administration (US FDA) has recently recommended label change for tamoxifen, to include pharmacogenetic information on treatment outcome. With the increasing availability of pharmacogenetic testing, on germline as well as somatic mutations, oncologists are now able to identify individuals at risk of severe treatment toxicity or poor treatment response. However, there are still knowledge gaps to fill before rationalised therapy based on pharmacogenetics can be fully integrated into clinical practice. This review provides an overview on the application of pharmacogenetic testing for germ line mutations in oncology to predict response and toxicity.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacogenética
/
Pruebas Genéticas
/
Resultado del Tratamiento
/
Usos Terapéuticos
/
Quimioterapia
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Genética
/
Genotipo
/
Células Germinativas
/
Métodos
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Annals of the Academy of Medicine, Singapore
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS